Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Tarsus Pharmaceuticals (TARS) Other Gross PP&E Adjustments (2020 - 2025)

Tarsus Pharmaceuticals has reported Other Gross PP&E Adjustments over the past 6 years, most recently at -$3.2 million for Q4 2025.

  • Quarterly results put Other Gross PP&E Adjustments at -$3.2 million for Q4 2025, down 212.52% from a year ago — trailing twelve months through Dec 2025 was -$3.2 million (down 212.52% YoY), and the annual figure for FY2025 was -$3.2 million, down 212.52%.
  • Other Gross PP&E Adjustments for Q4 2025 was -$3.2 million at Tarsus Pharmaceuticals, down from -$2.1 million in the prior quarter.
  • Over the last five years, Other Gross PP&E Adjustments for TARS hit a ceiling of $4.9 million in Q2 2025 and a floor of -$3.2 million in Q4 2025.
  • Median Other Gross PP&E Adjustments over the past 5 years was $243500.0 (2022), compared with a mean of $286350.0.
  • Biggest five-year swings in Other Gross PP&E Adjustments: plummeted 1226.88% in 2021 and later soared 692.37% in 2024.
  • Tarsus Pharmaceuticals' Other Gross PP&E Adjustments stood at -$1.2 million in 2021, then increased by 3.48% to -$1.2 million in 2022, then crashed by 140.89% to -$2.9 million in 2023, then skyrocketed by 64.38% to -$1.0 million in 2024, then plummeted by 212.52% to -$3.2 million in 2025.
  • The last three reported values for Other Gross PP&E Adjustments were -$3.2 million (Q4 2025), -$2.1 million (Q3 2025), and $4.9 million (Q2 2025) per Business Quant data.